Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_assertion type Assertion NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_head.
- NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_assertion description "[Pathological samples of SCLC also expressed IGFBP-2 abundantly, as compared with NSCLC, and showed only rare (8%) IGFBP-2 promoter methylation, whereas the IGFBP-2 promoter was methylated in 71% of adenocarcinomas and 29% of squamous cell carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_provenance.
- NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_assertion evidence source_evidence_literature NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_provenance.
- NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_assertion SIO_000772 19679880 NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_provenance.
- NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_assertion wasDerivedFrom befree-20150227 NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_provenance.
- NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_assertion wasGeneratedBy ECO_0000203 NP484700.RA6iXO4mU8CxBSmwBPXQ8KtZaMRaCpX6ME-FdW2QTVI8s130_provenance.